Celldex Therapeutics (STU:TCE2) Construction In Progress : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Construction In Progress?

Celldex Therapeutics's quarterly construction in progress increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.72 Mil) but then declined from Dec. 2023 (€0.72 Mil) to Mar. 2024 (€0.00 Mil).

Celldex Therapeutics's annual construction in progress declined from Dec. 2021 (€0.56 Mil) to Dec. 2022 (€0.47 Mil) but then increased from Dec. 2022 (€0.47 Mil) to Dec. 2023 (€0.72 Mil).

Celldex Therapeutics Construction In Progress Historical Data

The historical data trend for Celldex Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Construction In Progress Chart

Celldex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

0.17

0.28

0.56

0.47

0.72

Celldex Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	0.72	-

Celldex Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Celldex Therapeutics (STU:TCE2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

CLDX:USA

Address

53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines